Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Liabilities and Shareholders Equity: 2019-2024

Historic Liabilities and Shareholders Equity for 4D Molecular Therapeutics (FDMT) over the last 6 years, with Dec 2024 value amounting to $560.4 million.

  • 4D Molecular Therapeutics' Liabilities and Shareholders Equity fell 29.81% to $424.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 billion, marking a year-over-year decrease of 10.04%. This contributed to the annual value of $560.4 million for FY2024, which is 64.87% up from last year.
  • According to the latest figures from FY2024, 4D Molecular Therapeutics' Liabilities and Shareholders Equity is $560.4 million, which was up 64.87% from $339.9 million recorded in FY2023.
  • 4D Molecular Therapeutics' 5-year Liabilities and Shareholders Equity high stood at $560.4 million for FY2024, and its period low was $261.8 million during FY2022.
  • Moreover, its 3-year median value for Liabilities and Shareholders Equity was $339.9 million (2023), whereas its average is $387.4 million.
  • Per our database at Business Quant, 4D Molecular Therapeutics' Liabilities and Shareholders Equity skyrocketed by 395.12% in 2020 and then dropped by 25.92% in 2022.
  • Over the past 5 years, 4D Molecular Therapeutics' Liabilities and Shareholders Equity (Yearly) stood at $288.3 million in 2020, then rose by 22.60% to $353.5 million in 2021, then fell by 25.92% to $261.8 million in 2022, then increased by 29.81% to $339.9 million in 2023, then skyrocketed by 64.87% to $560.4 million in 2024.